Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Stomach Neoplasms 10Carcinoma, Hepatocellular 10Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Recurrence 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Spinocerebellar Degenerations 1Solid Tumor 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Rare Tumour 1Pancreatic Neoplasms 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Hodgkin Disease 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

sintilimab 1pembrolizumab 1Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Endometrioid × sintilimab × Clear all
NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Peking University People's Hospital

Phase NA Not yet recruiting
10 enrolled
Gynecologic

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡